BindPro™ A Protein Removal Reagent Cited In US Patent 20120296189 Titled Methods of Collecting and Analyzing Samples From Human Interstitial Fluid
MONMOUTH JUNCTION, NJ.– Inventors John Bhogal, Alva Karinka, Timothy Henning, David Cunningham, Udo Hoss, Andrew Naegeli, John Latour and assignee Abbott Diabetes Care Inc published United States Patent Application 20120296189 titled, Methods of Collecting and Analyzing Samples. The patent cites BindPro™ from Biotech Support Group and details a method for measuring interstitial fluid glucose concentration via ion chromatography. The patent describes methods for measuring analyte concentrations in interstitial fluid samples and methods of extracting interstitial fluid.
The NERL D-Glucose standard of known concentration assay method was implemented to determine the concentration of glucose in samples. Standard solutions were prepared by adding volume of NERL D-Glucose standard solution with DI water followed by mixing and transfer to a microfuge tube. BindPro™ suspension was added to the tube and the filtrate was placed on an autosampler vial. Duplicate standard solutions were prepared with different concentrations and volumes. For clinical sample preparation, human interstitial fluid (ISF) in aqueous benzoic acid solution was frozen until ion chromatography analysis. The clinical samples are thawed and BindPro™ is added and filtrate is transferred to the autosampler vial. The samples are prepared for ion chromatography injection sequence for analyzing interstitial fluid samples.
For detailed protocols of the published article click
Characteristics Of BindPro™ Metabolomics - Protein Removal & Enrichment of Metabolites/Analytes From Serum or Plasma
- Protein removal >95% from serum, plasma, tissue etc.
- Linearly scaleable, unlike chemical precipitation or membrane filtration.
- Fast process, less than 30 minutes from application to separation
- Applicable for drug binding/screening and metabolomics
- Removes proteins from many species including human, mouse, sheep, bovine, goat, rat, and calf
- The process could be scaled up or down.
- The bound protein can be eluted from the surface quantitatively.
- It is supplied as dry powder.
- Compatible with high throughput systems such as 96 well plate.
BindPro™ is an umbrella trademark for polymeric reagents designed as alternative to ultrafiltration and solvent precipitation for applications that require protein removal and/or concentration in a more versatile or scaleable format. BindPro™ can be used in lieu of solvents for drug binding studies, especially useful for analytes or metabolites.
For more information, visit:
BindPro™ Metabolomics - Protein Removal & Enrichment of Metabolites/Analytes From Serum or Plasma
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it's principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to: www.biotechsupportgroup.com
Dr. Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
Bhogal, John, Shridhara Alva Karinka, Timothy P. Henning, David Cunningham, Udo Hoss, Andrew H. Naegeli, and John Latour. "Methods of Collecting and Analyzing Samples." U.S. Patent 20,120,296,189, issued November 22, 2012.
Turner, Joseph D., R. Stuart Langley, Kelly L. Johnston, Katrin Gentil, Louise Ford, Bo Wu, Maia Graham et al. "Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis." Journal of Biological Chemistry 284, no. 33 (2009): 22364-22378.
Suggested Related References
Kiang, Tony KL, Veronika Schmitt, Mary HH Ensom, Beverly Chua, and Urs O. Häfeli. "Therapeutic drug monitoring in interstitial fluid: A feasibility study using a comprehensive panel of drugs." Journal of Pharmaceutical Sciences (2012).
Sakaguchi, Kazuhiko, Yushi Hirota, Naoko Hashimoto, Wataru Ogawa, Toshiyuki Sato, Seiki Okada, Kei Hagino et al. "A Minimally Invasive System for Glucose Area Under the Curve Measurement Using Interstitial Fluid Extraction Technology: Evaluation of the Accuracy and Usefulness with Oral Glucose Tolerance Tests in Subjects With and Without Diabetes." Diabetes Technology & Therapeutics 14, no. 6 (2012): 485-491.